PARSIPPANY, NJ (MARKET WIRE) Preliminary results from a dose titration study showed that treatment with the fixed-dose combination therapy AZOR® (amlodipine and olmesartan medoxomil) helped the majority (cumulative 75.8 percent) of hypertensive patients to reach systolic blood pressure goals of < 140 mm Hg ( < 130 mm Hg for patients with diabetes) at any time point during the first 12 weeks and 66.1 percent non-cumulative at Week 12. The primary endpoint of the study was the percentage of patients achieving seated systolic blood pressure goal of < 140 mm Hg ( < 130 mm Hg patients with diabetes) cumulatively by Week